drugset
drugset / Trial / NCT01951846

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

NCT01951846 ↗

Phase 1 Completed 61 enrolled Boehringer Ingelheim
Non-randomizedSingle-groupOpen-label

Summary

The primary objective of this study was to determine the maximum tolerated dose (MTD) of BIBF 1120 in patients with solid tumours by the monitoring of drug-related adverse events. Secondary objectives were the evaluation of safety, efficacy, pharmacokinetics, and pharmacodynamics.

Timeline

Start
2002-11
Primary completion
2004-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Nintedanib Small molecule — Oral

Indications

cancer